Analystreport

Can-Fite BioPharma (NYSE:CANF) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $11.00 price target on the stock.

Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares  (CANF) 
NASDAQ:AMEX Investor Relations: ir.canfite.com